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Overall mortalityAbstract Aims: The aim of this consensus paper is to review the available evidence on the
association between moderate alcohol use, health and disease and to provide a working docu-
ment to the scientific and health professional communities.
Data synthesis: In healthy adults and in the elderly, spontaneous consumption of alcoholic
beverages within 30 g ethanol/d for men and 15 g/d for women is to be considered acceptable
and do not deserve intervention by the primary care physician or the health professional in
charge. Patients with increased risk for specific diseases, for example, women with familiar
history of breast cancer, or subjects with familiar history of early cardiovascular disease,
or cardiovascular patients should discuss with their physician their drinking habits.
No abstainer should be advised to drink for health reasons. Alcohol use must be discouraged
in specific physiological or personal situations or in selected age classes (children and adoles-
cents, pregnant and lactating women and recovering alcoholics). Moreover, the possible inter-
actions between alcohol and acute or chronic drug use must be discussed with the primary care
physician.
Conclusions: The choice to consume alcohol should be based on individual considerations, tak-
ing into account the influence on health and diet, the risk of alcoholism and abuse, the effect
on behaviour and other factors that may vary with age and lifestyle. Moderation in drinking and
development of an associated lifestyle culture should be fostered.
ª 2013 Elsevier B.V. All rights reserved.Alcoholic beverages are being consumed for millennia:
humans drink them for pleasure, for their energy content or
for behavioural and ritual reasons. Starting from the second
half of the last century, an increasing number of studies e
mostly epidemiological in nature e carefully examined the
associations between consumption of alcohol and human
health. The general view, at that time, was that, while
excessive alcohol consumption is noxious and clearly asso-
ciated with increased incidence of disease, moderate con-
sumption might be associated with reduced cardiovascular
risk. Further studies associated moderate consumption of
alcohol with reduced incidence also of metabolic and
neurodegenerative diseases. Conversely, a positive associa-
tion has been reported with increased risk of developing
some neoplasias. The World Health Organization (WHO) has
a ‘zero tolerance’ policy on alcohol consumption, but anintense scientific debate is currently taking place to confirm
or dispute such an approach.
The aim of this consensus paper is to review the available
evidence on the association between moderate alcohol use,
health and disease and to provide a working document to the
scientific and health professional communities.Methodology
The Nutrition Foundation of Italy coordinated a team
of Italian experts, as follows: selected Italian scientific soci-
eties were contacted and required to provide topic-specific
reviews of the alcoholehealth relation. Twenty societies out
of 23 agreed (see Appendix 1), although one finally chose not
to contribute to this document. All contributions were
Moderate alcohol use and health 489merged, discussed and agreed upon by the entire Panel,
which approved the final paper in September 2012.1 By definition, one drink is a standard w150 ml wine glass, or a
can of beer, or a standard shot glassw40 ml of liquor. This standard
drink contains w12 g of ethanol.Methodological limitations in the assessment of
alcoholehealth associations
All studies on the associations between alcohol and health
are methodologically complex. This is due to the methods
used to assess alcohol consumption, to the choice of
control groups and to the correct definition of confounding
factors. Assessment of alcohol consumption is usually done
by specific questionnaires, where frequency and amount
of consumption are collected. This procedure often un-
derestimates the true rate of consumption, especially in
heavy drinkers, who tend to report lower-than-habitual use
[1]. Such evaluation bias raises some interpretation issues:
a) when excessive alcohol consumption is found to have
untoward effects, these are attributed to intakes that are
lower than that inducing the effects and b) concerning
healthy effects attributed to moderate alcohol consump-
tion, an underestimation of ‘optimal’ intake and of the
minimal levels at which the benefits would disappear, will
be computed [2].
Because the alcoholehealth association not only de-
pends on quantities but also on patterns of alcohol use (in
other words, whether intakes are concentrated on times
such as the weekends or are regularly spread during weekly
meals), it is also important to clearly take such patterns
into account in addition to the mere quantities [1,2]
The selection of control groups is crucial in studies that
associate alcohol and health. Usually, abstainers are chosen
as the reference group, whereas drinkers are classified
based on levels of intake. However, the group of ‘ab-
stainers’ often includes subjects who report rare though
not nil consumption. Given that such subjects may under-
report their intakes, the contribution of their inclusion
among the controls to the overall effect might not be
negligible [3]. Former drinkers too are often included in the
teetotallers’ group. Notably, those who quit drinking often
do so because of health reasons. The inclusion of these
subjects in control groups might place the latter at a false
higher risk level (‘sick-quitter hypothesis’) [4]. Therefore,
ex-drinkers should only be included in ad-hoc categories.
Moderate consumption of alcoholic beverages has often
been associated with healthier lifestyles and higher socio-
economic status (though with cigarette smoking too) [5].
These associations might explain, at least in part, the
apparent reduced risk of cardiovascular disease (CVD) and
overall mortality in moderate drinkers vs. teetotallers [4].
In any event, these important confounding factors should
be carefully taken into account when performing or ana-
lysing association studies [3,4].
Another caveat in statements on alcohol and health is
related to the current absence of randomised clinical trials.
Indeed, all currently available data are based on observa-
tional studies. While randomised clinical trials would even-
tually contribute to better clarify the role of alcohol in
human health, such studies are obviously very difficult to
perform for both practical and ethical reasons [3,4,6].
In summary, epidemiological analyses of the association
between alcohol and health are complex and require keenattention to the various confounders, bias, and methodo-
logical issues that might lead to unsound conclusions.Alcohol and CVD disease
Coronary heart disease and fatal arrhythmia
Data derived from epidemiological studies and obtained in
primary care individuals consistently show the existence of
a significant inverse association between moderate alcohol
use and cardiovascular risk (mainly, myocardial infarction
and stroke). Conversely, excessive intake does increase
cardiovascular risk. Several meta-analyses reported a ‘J’-
shaped curve that describes the association between
alcohol consumption and cardiovascular risk, namely a
higher risk associated to both abstention and excessive in-
takes as compared with moderate consumption. The
maximal reduction of cardiovascular risk (fatal and non-
fatal events) associated with moderate consumption has
been estimated to be approximately 30%.
In some studies, actually, the inverse association be-
tween alcohol use and infarction risk reduction appeared
to be linear, that is increasing alcohol consumption
correlated with a continually decreasing risk. Such asso-
ciation was observed, as an example, in the Health Pro-
fessional cohort [5], in which maximum protection was
observed in consumers of 50 g or more of alcohol, that is
four drinks1 per day. A recent meta-analysis [7] reported a
“J” association in women but not in men, in whom higher
levels of intake were associated with lower coronary risk.
In this meta-analysis, the protective effect was seen in all
age groups, even though risk reduction e in absolute terms
e increased with age. In the most recent meta-analysis by
Ronksley et al. [8], consumption of alcoholic beverages
was associated with a 25e50% reduction of fatal and non-
fatal coronary event risk as compared with teetotallers.
Low-to-moderate alcohol consumption was associated
with a reduction of cardiovascular and all-cause risk
reduction also in a cohort of 14,125 hypertensive men
selected from the Physicians’ Health Study [9]; a further
analysis of the same cohort reported an inverse associa-
tion between moderate alcohol use and incidence of
coronary heart disease (CHD). In this analysis, risk
reduction was 40% in subjects who drank more than eight
drinks/week.
In diabetic subjects a meta-analysis of six prospective
studies evidenced a close association between moderate
alcohol consumption and reduced coronary disease; the
reduction of relative risk (RR) was similar in magnitude to
that seen in the general population and in hypertensive
patients [10].
Less evidence is presently available to describe the ef-
fects of alcohol in patients with pre-existing CHD [11,12]. A
recent meta-analysis of eight studies involving a total of
16,531 subjects with cardiovascular events reported that a
low-to-moderate (5e25 g/d) alcohol consumption is asso-
ciated with a significantly lower incidence of cardiovascular
490 A. Poli et al.and all-cause mortality. These data confirm in CHD patients
what has been observed in healthy subjects. A positive
effect of moderate alcohol consumption was also apparent
in patients who underwent angioplasty procedures, in
whom both atherosclerosis progression and clinical relapses
appeared to be positively influenced by alcohol intake
[6,13].
In the area of secondary prevention, one aspect that
deserves attention is the possible interaction between
alcohol and pharmacological therapy. In particular, close
attention should be paid to the interaction between alcohol
and anti-platelet drugs or oral anticoagulants, which can
increase the risk of haemorrhages.
As far as arrhythmias are concerned, binge drinking has
been associated with increased risk of atrial fibrillation, that
is, the so-called ‘holiday heart syndrome’. Recently, it was
suggested that even the habitual intake of high alcohol doses
(35 drinks/week or more) might correlate with arrhythmia
risk [14e16]. A recent meta-analysis indicated a linear,
doseeresponse association between alcohol use and risk of
atrial fibrillation [17]. These data suggest that the risk of
arrhythmia proportionally increases with daily doses of
alcohol; presumably, a reduction of alcohol consumption or
even abstinence would be associated with lower atrial
fibrillation risk. Conversely, sudden death due to ventricular
arrhythmias was reportedly less frequent in both men and
women who consumed approximately one drink/d [18,19].
In summary, as far as primary prevention is concerned,
moderate alcohol use by apparently healthy individuals is
associated with significant reduction of cardiovascular risk
and sudden death due to ventricular arrhythmias. The
presence of risk factors such as hypertension does not seem
to markedly modify this association. Patients with pre-
existing CVD could get similar benefits from moderate
alcohol consumption but should pay attention to the possible
interaction of alcohol with their pharmacological regimen.
Excessive alcohol consumption is specifically dangerous for
patients with cardiomyopathy or supraventricular arrhyth-
mias, being able to worsen their arrhythmic risk.Stroke
Several prospective studies evaluated the association be-
tween alcohol consumption and risk of stroke. Most studies
reported a ‘J’-shaped association, especially concerning
ischaemic strokes; because of the relatively low incidence
of haemorrhagic stroke, the effects of alcohol on total
strokes are similar to those observed for ischaemic
strokes.
A meta-analysis of both cohort and caseecontrol studies
[20] reported a ‘J’-shaped association between alcohol
consumption and total and ischaemic stroke risk, while a
linear positive association was observed between alcohol
intake and haemorrhagic stroke. In particular, subjects who
consumed <12 g or between 12 and 24 g/d of alcohol, that
is one to two drinks/d were attributed a significantly
reduced risk as compared with teetotallers (RRZ 0.80 and
0.72, respectively). Higher alcohol consumption, that is
more than 60 g, or five drinks/d was conversely associated
with a significant increase of both ischaemic (RR Z 1.69)
and haemorrhagic (RR Z 2.18) strokes. A more recentmeta-analysis [21] confirmed these data, which were not
modified following adjustment for cerebrovascular mortal-
ity and morbidity. Finally, the most recent meta-analysis on
this topic [8] e which pooled a sample of hundreds of
thousands of individuals e indicates that stroke risk
reduction (both as mortality and incidence) is significant
only in association with a daily alcohol intake between 2.5
and 14.9 g (RR Z 0.86 and 0.80, respectively).
In the Reynolds et al. meta-analysis [20], stroke RR as
associated with alcohol intake was also analysed for sex.
Even though the ‘J’-shaped curve was seen in both sexes,
stroke RR for consumptions >60 g, that is five drinks/d was
higher in women than in men (RR Z 4.29 and 1.76 vs. ab-
stainers, respectively). The fact that women appear to be
more sensitive to the effects of high intakes was confirmed
by Ronksley et al. [8], who specifically analysed haemor-
rhagic stroke. However, the Nurses’ Health Study (NHS) e
maybe because of the limited number of subjects who
consumed elevated alcohol quantities e did not report such
an untoward effect [22].
Few studies separately analysed the role played by
different alcoholic beverages on stroke risk. The results of
the Stroke Prevention in Young Women Study [23] suggest
that wine exerts protective effects that were not recorded
for either beer or liquor. In a meta-analysis of the effects of
alcohol on cerebrovascular diseases [24], a stratified analysis
also suggested protective effects of wine, but not of beer,
consumption. Conversely, no significant difference was
observed among the various kinds of beverages within the
Framingham [25] and the Northern Manhattan Studies [26].
Data on the protective effects of moderate alcohol
consumption are corroborated by the EPIC Norfolk (Norfolk
cohort of European Prospective Investigation of Cancer
study), where more than 20,000 subjects were followed up
for over a decade. This study underscored the interaction
between alcohol consumption and ‘healthy’ lifestyles that
include abstinence from smoking, appropriate diet and
physical exercise. These four features halved stroke risk as
compared with people who did not follow such guidelines.
The adoption of one to three of these indications reduced
risk to a significantly lower extent [27].
The results of the Physician’s Health Study suggest that
low-to-moderate alcohol consumption and stroke-risk
reduction are also associated in secondary prevention
[28]. Patients who drank in moderation exhibited lower
cardiovascular mortality (though not specifically for stroke)
as compared with non-drinkers. It must be underlined that
risk evaluation should be exerted with great care on indi-
vidual bases. A recent study [29] suggests that the protec-
tive effects of moderate alcohol intake on stroke risk can
be significantly attenuated in the presence of high serum
concentrations of gamma-glutamyltransferase (gamma-
GT), which postulates an inadequate estimate of alcohol
consumption or concomitant diseases that would reduce
any beneficial effect.
Binge drinking [30] is usually associated with more
elevated stroke risk, possibly because of the increase in
blood pressure that follows large alcohol intakes [31].
Accordingly, increased risk within the first two hours of
alcohol assumption has been reported at all levels of con-
sumption [32]. Apparently, this phenomenon is transitory
and, within 24 h, risk ratios return to ‘habitual’ values.
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reduced risk of total stroke and notably of ischaemic
events; conversely, consumption of elevated quantities of
alcohol is an important risk factor for any type of stroke.Peripheral artery disease
Several pieces of evidence, as discussed above [24,33,34],
support an inverse association between alcohol use and
acute CVD risk; conversely, the risk of developing non-acute
atherosclerotic diseases in relation to alcohol use has been
poorly investigated. Among such disorders, peripheral artery
disease (PAD) has a high prevalence and concerns >5% of
subjects older than 60 years [35]; PAD itself is considered as a
main cause of disability. Indeed, PAD patients are exposed to
complications that may lead to amputation and experience
an increased incidence of cardiovascular events such as
myocardial infarction, ischaemic stroke and cardiovascular
death. Therefore, PAD can be considered a marker of sys-
temic atherosclerosis and its early diagnosis might be useful
in identifying patients at high cardiovascular risk. The evi-
dence of a link between alcohol intake and PAD is modest if
compared with that relative to coronary or cerebrovascular
disorders (see above). Among the studies that took such a
possible association into consideration, both the Strong
Heart Study [36] and the Rotterdam Study [37] reported an
inverse association between moderate alcohol use and PAD
diagnosis (based on reduced Winsor indices). Such an asso-
ciation appears to be stronger in women than in men, even
though another study reported the converse [38]. A subse-
quent sub-analysis of one of the two studies mentioned
above,whichexaminedPADprogression, recordedan inverse
association between alcohol consumption and variation at 5
years of the Winsor index [39].
Two prospective studies evaluated the association be-
tween alcohol use and PAD risk in the general population. In
an analysis from the Framingham Heart Study [40], which
selected symptomatic PAD as the ‘end’ point, the authors
reported a hazard ratio of 0.67 associated with a con-
sumption of 13e24 g/d, that is, one to two drinks/d for men
and of 0.44 associated with a consumption of 7e12 g/d,
that is, one half to one drink/d for women. In the Physi-
cians’ Health Study, Camargo et al. [41] reported a hazard
ratio of 0.74 associated with a consumption of seven or
more drinks/week; the analysis, on the other hand,
included only 66 PAD cases. In the latter study, alcohol use
was associated with a 26% risk reduction of claudicatio
intermittens. Another study, however, carried out in a
diabetes mellitus cohort did not report any association
between alcohol consumption and PAD [42]. Although PAD
risk reduction was associated with preferential consump-
tion of wine or beer in the Framingham Study [40], or with
wine consumption in a sub-analysis of the Edinburgh Artery
Study [38], the majority of studies failed to attribute the
observed reduced risk of developing PAD to any particular
alcoholic beverage.
Finally, a limited number of studies evaluated the asso-
ciation betweenmoderate alcohol use and risk of developing
abdominal aorta aneurysms (AAAs). An analysis of male
smokers reported a ‘U’-shaped association curve between
alcohol intake and AAA risk, with RR reductions ranging from0.74 for consumptions up to 15 g/d to 0.60 for intakes up to
30 g/d and increased risk for higher intakes [43].
In summary, the association between moderate alcohol
consumption and extra-coronary CVD is complex and het-
erogeneous. In particular, epidemiological studies confirm
that PAD risk is reduced by moderate alcohol intake, that is,
in the one to two drinks/d range. However, larger pro-
spective studies are necessary to more precisely define the
association between alcohol use and peripheral vascular
disorders and to formulate recommendations.Alcohol and cardiovascular risk factors
Lipid profile
An early review, published in 1999 [44], suggested that
moderate alcohol use is associated with increased plasma
concentrations of high-density lipoprotein (HDL) cholesterol
(HDL-c), with a clear doseeresponse relationship, namely,
an increase of 0.133mg/dl for every gramof alcohol ingested
daily. Likewise, every gram of alcohol was associated with a
0.294 mg/dl increase in plasma apolipoprotein A-I levels
(Apo-AI; the foremost component of HDL) and of 0.190mg/dl
in triacylglycerol (TG) plasma levels. Total cholesterolaemia
was not influenced by alcohol intake, while TG increase was
more obvious in the post-prandial phase.
Alcohol consumption would induce increased hepatic
synthesis of Apo-AI, Apo-AII and of HDL-C and its sub-
fractions HDL1, HDL2 and, notably, HDL3 via increased ac-
tivity of lipoprotein lipase (LPL) [45]. Alcohol might also
influence the activity of other key metabolic enzymes such
as lecithin:cholesterol acyl-transferase (LCAT) and
cholesterol-ester-transfer protein (CETP). In particular,
alcohol increases LCAT activity while decreasing CETP, in
turn increasing HDL-c concentrations and reverse choles-
terol transport [46].
It remains however to be established whether alcohol-
induced increase of HDL-c concentrations would entirely
explain its cardioprotective properties. Indeed, on the one
hand intervention studies failed to show that increasing
HDL-c lowers cardiovascular mortality [47]; on the other,
HDL exerts a number of cardioprotective actions including
reduced low-density lipoprotein (LDL) oxidation, inhibition
of inflammatory molecules migration into the sub-
endothelial space and reverse cholesterol transport [48].
In summary, moderate alcohol use dose-dependently
increases HDL-c and Apo-AI (see also a recent meta-analysis
by Brien et al.[49]). Conversely, no significant alterations of
total and LDL-c are observed. Increased TGs usually occur
after the ingestion of >60 g/d, that is, five drinks/d of
alcohol only. These overall favourable effects might
contribute to the reduction of cardiovascular risk observed
in moderate alcohol drinkers.Blood pressure
The effects of alcohol on blood pressure are manifold. Only
modest intakes appear to be healthful; usually, a linear
association between alcohol intake and increased blood
pressure is reported in both normal subjects and
Table 1 Effects of moderate alcohol consumption on the
main markers of inflammation and on hemostasis factors in
epidemiological and intervention studies.
Epidemiological
studies
Intervention
studies
C-reactive protein (CRP) þþþ þ/
Interleukin-6 (IL-6) þ þ/
Tumour necrosis factor-a
(TNF-a)
þ/ þ/
Fibrinogen þþ þþþ
Plasminogen activator
inhibitor-1 (PAI-1)
þ/ þ/
Tissue plasminogen
activator (TPA)
þ/ þ/
Adiponectin þ þþ
Effects: þ/ uncertain; þ modest; þþ strong; þþþ very
strong.
492 A. Poli et al.hypertensive patients [50,51]. The hypertensive effect of
alcohol, in interventional studies, is yet reversible [51]
Several observational studies suggested that intake of
alcohol in excess increases blood pressure [52]. Klatsky
et al. evaluated blood-pressure changes as related to
alcohol use in 83,947 men and women and concluded that
those who consumed >3 drinks/d had higher systolic and
diastolic pressure values as compared with teetotallers
[53]. In 1995, Gillman et al. reported e in young adults e a
‘J’-shaped association between alcohol use and blood
pressure, minimal values being noted in those who
consumed one or two drinks/d [54]. A simple linear asso-
ciation was, in contrast, reported by others [55]. Compul-
sive drinkers exhibit higher risk for stroke in the early
morning, which has been tentatively linked to a possible
circadian effect of alcohol on blood pressure [56]. Con-
sumption of several drinks in the evening appears to induce
a moderate increase in daytime pressure but a reduction in
the night-time one. The net effect is that of a mild overall
increase, at least in Japanese subjects [57]. Normotensive
subjects from the Women’s Health Study and Physicians’
Health Study cohorts have been examined to ascertain the
risk of developing hypertension in relation with alcohol
consumption. This analysis concerned 28,848 healthy
women and 13,455 healthy men. The results show a
decreased risk of incident hypertension in drinking women,
but an increased risk in men as compared with abstainers.
Consumption threshold, apparently, is four drinks a day for
women vs. just one drink for men [58]. Some authors
observed that acute alcohol ingestion was associated with a
sudden drop in blood pressure (because of either direct or
indirect vasodilatory effects), followed by an increase [59].
Genetic polymorphisms of enzymes that metabolise
alcohol, for example aldehyde dehydroxygenase, might
influence their effects on blood pressure [60].
The mechanism(s) by which ethanol influences blood
pressure have not been clarified yet. While alcohol itself
might stimulate the production of endothelin ET-1, whose
urinary excretion is in fact increased by alcoholic beverages
[51], red wine polyphenols might reduce its synthesis by
inhibition of ET1 gene transcription [61]. Endothelial
function might also augment after red wine ingestion
[62e64], possibly independent from an effect of alcohol
per se [63]. However, ad-hoc clinical studies measuring
flow-mediated dilation yielded mixed results [65].
In summary, available data suggest that alcohol in very
moderate amounts appears to exert neutral or beneficial
effects on blood pressure and that red wine might be su-
perior to other alcoholic beverages [24,66,67]. Because
moderate alcohol use is being associated with better car-
diovascular prognosis in hypertensive patients, consump-
tion levels of <30 g/d, that is 2.5 drinks/d for men and
<15 g/d, that is wone drink/d for women, though hyper-
tensive, might be advantageous over abstention [57].Inflammation and circulating surrogate markers
of CVD
Several epidemiological studies reported an association
between moderate alcohol intake and low plasma concen-
trations of inflammation markers (Table 1). A study carriedout on two large cohorts, that is men from the Health
Professionals Follow-up Study, HPFS, and women from
the Nurses’ Health Study II, NHSII, reported that, in com-
parison to abstainers, 15e30 g/d alcohol consumption was
associated with a reduction in serum concentrations of
C-reactive protein (CRP), interleukin 6 (IL-6) and the solu-
ble tumour necrosis factor-alpha (TNF-alpha) receptors,
sTNF-R1 and sTNF-R2 [68]. Men who consumed one or two
drinks/d had 26% CRP and 36% IL-6 lower concentrations
than teetotallers. Women exhibited a similar trend at half
of the intake levels of men [68]. Similar results have also
been reported by Imhof et al. [69], who showed a ‘U’-
shaped relationship between serum CRP concentration and
alcohol intake. In particular, lower serum CRP levels were
observed at 20e40 g/d alcohol intake, while higher con-
centrations were found at 80 g/d alcohol intake [69]. The
purported anti-inflammatory effect of alcohol intake up to
40 g/d has been confirmed in many European populations, in
which lower serum fibrinogen and leucocyte concentrations
and decreased haematic viscosity have been found to be
associated with reduced CRP levels in moderate drinkers,
regardless of the kind of drink [70]. Other studies, for
example the Health, Aging and Body Composition Study,
investigated the association between IL-6 and alcohol con-
sumption, thus highlighting a ‘J’-shaped curve, with the
nadir placed at one-to-seven drinks/week [71]. A similar
pattern has also beenobserved for CRP, but not for TNF-alpha
and plasminogen activator inhibitor-1 (PAI-1). In addition in
diabetic patients,moderate alcohol intake is associatedwith
lower serum concentrations of fibrinogen, sTNF-R2 and sol-
uble vascular adhesion molecule-1 (sVCAM-1) as well as
higher levels of adiponectin [72].
Although methodological differences in alcohol-intake
assessment impair conclusive results, the overall body of
evidence seems to suggest an anti-inflammatory effect of
restrained alcohol consumption. However, the ‘J’- and ‘U’-
shaped curves mentioned above are indicative of a
threshold value over which alcohol intake may have a pro-
inflammatory effect.
The few intervention studies that investigated the
effects of moderate alcohol consumption on circulating
Moderate alcohol use and health 493concentrations of PCR, IL-6, TNF-alpha, PAI-1 and tissue
plasminogen activator (TPA) yielded conflicting results
(Table 1). A recent meta-analysis showed that low alcohol
intake reduces serum concentrations of PCR, IL-6 and TNF-
alpha, although to a non-significant extent [49]. This meta-
analysis only included five studies on CRP, three on TNF-
alpha and two on IL-6. Conversely, alcohol consumption
significantly increases adiponectin (four studies) and de-
creases fibrinogen (seven studies) by an average of 0.20 g/l,
whichmight contribute to its hypothesised cardio-protective
effects [73]. As far as adiponectin is concerned, theeffects of
alcohol are unclear and data are scant. Moderate alcohol
consumption increases adiponectin concentrations by
0.6 mg/L on average [74], that is, an increase similar to that
produced by the powerful insulin-sensitisers thiazoline-
diones [75].
The effects of alcohol on other haemostatic parameters
such as plasminogen, thromboxane, von Willebrand’s factor
and E-selectin as well as those on endothelial markers, for
example intracellular adhesion molecule 1 (ICAM) and VCAM
are still unclear as data are insufficient and conflicting.
Metabolic effects of alcohol
Metabolic syndrome
The metabolic syndrome (MS) is a multifactorial disorder
that, according to the recent International Diabetes Feder-
ation definition, requires the presence of central obesity and
at least two of the four following abnormalities: high TGs,
low HDL-c, high blood pressure or raised fasting plasma
glucose level. According to the Adult Treatment Panel-III
(ATP-III) definition (with which the general practitioner is
more familiar), the presence of any three of the five risk
factors mentioned above allows to diagnose the MS [76].
The relation between alcohol intake and MS prevalence is
controversial, as alcohol has positive effects on some of its
factors, for exampleHDL-c serumconcentrations and negative
effects on other ones, for example blood pressure levels [77].
Observational studies from different geographic areas
report reduced MS prevalence in moderate drinkers and an
increase of MS prevalence in abstainers, heavy drinkers and
those who started to drink early in their lives. Therefore the
relation between alcohol consumption and MS risk is ‘J’- or
‘U’-shaped. Freiberg et al. [78] observed in low-to-moderateTable 2 Relative risk of metabolic syndrome as related to the
analysis of seven observational studies.
Alcohol
consumption
Category 1
0e39.9 g/d
Categ
40e59
Men RR (95% CI): 0.84 (0.75, 0.94)
P Z 0.004
RR (95
P Z 0
Women Category 1
0e19.9 g/d
Categ
20e39
RR (95% CI): 0.75 (0.64, 0.89)
P Z 0.0007
RR (95
P Z 0
RR, Relative Risk; CI, Confidence Interval. Modified from Alkerwi A et
different between men and women.drinkers a reduced MS prevalence of 48% in men and 47% in
women younger than 50, regardless of ethnic origin, in
comparison to abstainers. This study, which individually
evaluated separately the various components of the MS,
suggested that moderate alcohol consumption was associ-
ated with reduced prevalence of low serum concentration of
HDL-c, high levels of TG and higher waist circumference, as
well as hyperinsulinaemia [78]. This association was stronger
in consumers of wine and beer, while liquor drinkers showed
only a favourable association with HDL-c levels. However,
other studies do not confirm the positive association be-
tween moderate alcohol consumption and MS risk. For
instance, a study carried out in Italy, performed on subjects
between 65 and 84 years of age, reported that moderate
alcohol intake significantly worsened, in men but not in
women, three out of the five components of MS, that is
systolic blood pressure, glycaemia and waist circumference,
suggesting a sex effect of ethanol [79].
Indeed, a recent meta-analysis that also took into ac-
count sex, showed that ethanol intake of <40 g/d, that is
w3.5 drinks/d in men and <20 g/d, that is w two drinks/
d in women reduces the risk of MS by 16% and 25%,
respectively, as compared with abstainers (Table 2) [80].Alcohol and insulin sensitivity
Thebeneficial effects ofmoderate alcohol consumptionon the
MS and some of its components have been attributed to an
amelioration of insulin sensitivity, partly mediated by lower
visceral adiposity. This effect, observed in several epidemio-
logical studies, has not been conclusively confirmed by inter-
vention studies that, being devoid of confounders, are the
most suitable for clarifying potential mechanisms of action.
In observational studies, alcohol consumption of 10e30 g/
d, that is w one or two drinks/d is associated with lower
fasting insulin concentrations and lower markers of insulin
resistance, under both fasting and glucose load conditions
[81,82]. In particular, theNormative Aging Study [81] showed
that the relation between alcohol intake and insulin sensi-
tivity markers is not linear, as consumers of one to two
drinks/d were less insulin-resistant than subjects who
consumed either less or more than this amount. On the
contrary, no association between alcohol, insulin sensitivity
(as evaluated by euglycaemic clamp) and insulin secretion
was reported by the Uppsala Longitudinal Study of Adult Menhabitual alcohol consumption of men and women: a meta-
ory 2
.9 g/d
Category 3
>60 g/d
% CI): 0.95 (0.83, 1.09)
.49
OR (95% CI): 0.99 (0.71, 1.38)
P Z 0.94
ory 2
.9 g/d
% CI): 0.81 (0.57, 1.14)
.22
d
al. [80]. Note that consumption levels used for computation are
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sumption and insulin resistance has been reported in normal-
weight subjects, but not in overweight/obese patientswith a
Homeostasis Model of Assessment (HOMA) index <2 [84].
The few available intervention studies provide controversial
results. However, themajority of them indicates that 25e39 g/
d ethanol consumption, that is w two or three drinks/d im-
proves lipid profile and insulin sensitivity as well as serum adi-
ponectin in menopausal women [85,86], while in men it seems
to have no influence on insulin sensitivity and fat distribution
and, indeed, it may promote hepatic steatosis [74,87].
In summary, epidemiological data support a reduction of
MS risk associated with low-to-moderate alcohol con-
sumption. This effect is particularly evident for some of the
MS components such as HDL-c and fasting insulin levels.
However, due to the limited sample size and short duration
(3e8 weeks), the few intervention studies do not allow
ascertaining the role of ethanol intake on insulin
sensitivity.
Alcohol, overweight and obesity
The addition of alcohol to a normocaloric diet should
increase body weight because of the added calories.
Moreover, alcohol increases appetite (due to its hypo-
glycaemic action) and facilitates socialisation, in turn
increasing food intake [88]. However, observational studies
failed to correlate alcohol use with body weight. In an
American women cohort, Wannamethee et al. [89]
observed that the lowest body mass index (BMI) values
were associated with alcohol intakes of 5e30 g/d; in a 13-
year follow-up, moderate alcohol use was also associated
with lower chance to gain weight or to become overweight
or obese [90]. Likewise, the National Health and Nutrition
Examination Survey (NNAHES) cohort exhibited a clear in-
verse association between moderate alcohol intake and
obesity risk (and, to a lower extent, overweight risk) [91].
In particular, total and abdominal adipose tissue in mod-
erate drinkers is reportedly less than that in abstainers or
heavy drinkers [92], even if an intervention study on 35e70-
year-old men failed to observe any variation of abdominal
fat following the consumption of 40 g de1 for 4 weeks [74].
In summary, the association between alcohol use and
body weight is multifaceted and difficult to correctly
compute, mostly because of the many confounding factors
that hamper its correct assessment. However, while
elevated alcohol intake is associated with increased risk of
obesity or overweight, moderate consumption appears to
have neutral or favourable effects [93].
Alcohol and diabetes
Alcohol consumption has always been considered a risk
factor for diabetes mellitus. However, recent publications
suggest that moderate alcohol use might actually be asso-
ciated with reduced incidence of type 2 diabetes mellitus
(T2DM) and its vascular complications.
Ameta-analysis by Koppes et al., which analysed 15 studies
on 369,862 patients followed up for an average of 12 years,
concluded that subjects who consumed 6e48 g/d, that is one-
half to four drinks/d of ethanol exhibited a 30% reduced risk ofT2DM as compared with teetotallers or consumers of >48 g/
d of ethanol [94]. This effect is independent of either sex or
BMI. In addition, a lower incidence of T2DM was observed in
women with moderate alcohol intake (but not in men) when
compared with abstainers in a prospective study by Hodge
et al. [95] Moderate alcohol use and reduction of cardiovas-
cular risk in diabetic patients are also associated [96].
Moderate alcohol consumption and cardiovascular risk in
diabetics have also been found to be inversely associated in
the Second Manifestations of ARTerial (SMART) disease
study [97]: moderate (10e20 drinks/week) ethanol use was
associated with reduced risk of acute coronary disease and
stroke (hazard ratio (HR) 0.39; confidence interval (CI):
0.20e0.76) as well as lower overall mortality (HR 0.40; CI
0.24e0.69), when compared with abstainers. This associa-
tion was also apparent when red wine was highlighted.
Recently, Djousse et al. [98], based on the results of an
investigation on 28,345 women, concluded that the positive
association between moderate alcohol use and cardiovas-
cular risk reduction can be partly explained by the benefi-
cial effects of ethanol on glucose metabolism, in addition
to lipid profile, inflammation and blood pressure.
Current guidelines addressed to diabetic patients are
rather cautious because of the calories and body-weight
issues, in addition to some untoward metabolic and
vascular effects of alcohol. In brief, such guidelines indi-
cate that if a diabetic adult chooses to drink alcohol, his/
her daily intake should be kept constantly modest (10e13 g,
i.e., one drink or less for women and 20e25 g, i.e., two
drinks/d or less for men). To reduce the risk of nocturnal
hypoglycaemia in patients on insulin or insulin secreta-
gogues, alcohol should be ingested with food [99].Moderate alcohol use and liver disease
Alcoholic liver disease (ALD) is the most prevalent cause of
advanced liver disease in the Western world. It comprises a
large spectrum of liver injuries, ranging from fatty liver or
simple steatosis (alcoholic fatty liver disease, AFLD) to
acute alcoholic hepatitis, alcoholic steatohepatitis (ASH),
chronic hepatitis with hepatic fibrosis and cirrhosis
[100,101]. Non-alcoholic fatty liver disease (NAFLD), on the
other hand, is the most common liver disorder in Western
countries and affects as many as 25e30% of adults. NAFLD
might shortly become the most common liver disease
worldwide [102].
The distinction between NAFLD and AFLD or between
NASH (non-alcoholic steatohepatitis) and ASH is based on
average daily alcohol consumption, the discriminating
threshold being 20e30 g/d [102] by international standards.
Therefore, proper diagnosis is based on daily alcohol-intake
determination. In clinical practise, this is usually done by
estimating the ‘drinks per day’ consumption (see above in
this paper for the definition of drink units) [103].
In the general population, the daily threshold of alcohol
intake associated with an increased risk of liver injury is
between one and two drinks per day for women and two and
threedrinks per day formen.Certainly, drinkers ofmore than
30e50g/dof alcohol formore than5e10years areexposed to
a significant risk to develop ALD. Not all these drinkers,
however, develop a liver disease. Indeed,we know that some
Moderate alcohol use and health 495host- and environment-related predisposing factors promote
ALD development [100,101]. For example, genetic poly-
morphisms of alcohol dehydrogenase and their interaction
with genes involved in the generation and scavenging of free
radicals influence susceptibility to ALD [100]. Obesity, dia-
betes, insulin resistance, metabolic syndrome (including
NAFLD) as well as hepatitis C virus (HCV) infection increase
the liver-damaging effects of alcohol [100,101].
Current belief is that low or moderate alcohol con-
sumption should be forbidden in patients with liver disease.
Therefore, subjects with chronic liver disease (regardless of
its aetiology), are usually warned by clinicians to avoid
any kind of alcoholic beverage. Conversely, whether mod-
erate, that is less than one to two units per day, that is
20e30 g/d daily alcohol intake could be safe in patients
with NAFLD remains an open issue.
Only 4e5%ofpatientswithNAFLD, namely those exhibiting
amore severe subtype known as steatohepatitis (NASH,which
is characterised by inflammatory infiltrates, ballooning he-
patocellular injury and fibrosis) are at a high risk for cirrhosis-
and hepatocellular carcinoma (HCC)-related mortality. We
also know that most non-cirrhotic NAFLD patients who are
moderatedrinkers are not at significant risk ofworsening their
liver disease [104e107]. Patients with NAFLD and, especially,
those with NASH, are e conversely e at increased risk for
cardiovascular or coronary-heart disease (CVD or CHD).
Indeed, they are twice more likely to die from CVD than from
liver diseases [108]. Evaluation of cardiovascular risk and
management of CHD risk factors is, therefore, mandatory in
these patients.
As moderate alcohol use not only is associated with
reduced CHD morbidity and mortality risk, but also im-
proves metabolic risk factors related to both CVD and
NAFLD [85,109] and seems to partially protect from NASH
and NAFLD [106,107], patients with NAFLD who drink no
more than two-three drinks per day could perhaps be
allowed to continue their drinking habits. This issue is,
however, still unresolved [110].Alcohol, cognitive impairment and dementia
Five epidemiological studies have been published on the
association between alcohol use and incidence of dementia
and Alzheimer’s disease [111e115]. In addition, two meta-
analyses examined 26 and 15 studies, respectively
[116,117].
The available evidence comes mostly from longitudinal
cohort studies, in which non-dement or mild cognitive
impairment (MCI) elderly have been followed to monitor
their cognitive performance. The results are summarised in
Table 3.
All studies revealed a reduction of dementias and Alz-
heimer’s risk associated with moderate alcohol use, as
compared with abstainers. The extent of risk reduction
greatly varies among studies and meta-analyses. All studies
reported a negative association between alcohol intake and
risk of dementia; publication bias is unlikely, but cannot be
ruled out. Alcohol would decrease cerebrovascular risk via
one or more mechanisms described above, such as its anti-
inflammatory effect [118]. This is supported by a recent
study showing that ethanol is able to reduce the synapticdamage induced by beta-amyloid and synuclein [119]. One
should not forget however that alcohol in excess causes
at least two well-known neurological diseases charac-
terised by cognitive decline and dementia, that is Wer-
nickeeKorsakoff’s and MarchiafavaeBignami’s syndromes,
and that an alcohol-mediated form of dementia has been
described, which is accompanied by cerebral atrophy and a
typical alteration of white and grey matters.
Alcohol, skeletal frailty and osteoporosis
Several observational studies indicate that alcohol con-
sumption might influence bone density, depending on
intake levels. In general, moderate alcohol use has no sig-
nificant influence on bone density (or it has even positive
effects), whereas data on heavy intake are conflicting,
mainly pointing to negative effects on bone structure.
The effects of two or three drinks/d depend on age, sex
and hormonal profile; for example positive effects are
described for menopausal, but not for fertile women. The
type of alcoholic beverage might also be important, as
favourable effects have also been reported separately for
wine [120] and beer [121]. These observations might be
explained by the non-alcoholic content of either beverage.
In a human study [122], consumption of two drinks/
d increased bone density, while more than two glasses/
d exerted detrimental effects on both spine and femur.
Finally, in a study carried out in twins with different alcohol
use, moderate consumption was associated with higher
bone mass [123]. A very recent and large study in post-
menopausal women observed that the association be-
tween moderate consumption and higher bone mass cannot
be explained by lifestyle, hence suggesting some direct
effect of ethanol [121].
As far as mechanisms of action are concerned, alcohol has
been suggested to slow bone resorption with no effects on
bone formation; in turn, the net consequence on mass would
be positive [124]. This hypothesis is partly confirmed by the
observation that low-to-moderate alcohol use, that is <27
drinks/week formenand<13drinks/week forwomenhas not
been associated with any increased fracture risk [125,126].
One note of caution concerns the deleterious effects of
high alcohol intake. Indeed, excessive and prolonged
alcohol consumption lowers bone density and is considered
a major risk factor for bone fractures [125,127].
Alcohol and cancer
Most cancers are reportedly not associated with moderate
alcohol intake. Only the association between light alcohol
consumption and cancer risk for sites for which sufficient or
limited evidence for carcinogenicity of alcohol is available
[128,129], that is, cancers of the upper digestive and res-
piratory tract (oral and pharyngeal cancer, oesophageal
squamous cell carcinoma and laryngeal cancer), color-
ectum, pancreas and breast will be examined in this paper.
Adenocarcinoma of the oesophagus will not examined
because this neoplasm is not to be associated to alcohol
drinking [130].
A positive association between alcohol and liver cancer
has been established [128]. However, the latter will not
Table 3 Original studies and meta-analyses of the associations between alcohol intake and dementia and/or cognitive decline.
Title Characteristics and
No. participants
Outcome (cases) Alcohol consumption Relative risk estimate (95% CI)
Alcohol consumption and risk
of dementia: the Rotterdam
Study [111].
Cohort population study on 7893
non-demented subjects
Dementia (197) AD (146) 1e3 drinks/d vs. nondrinkers 0$58 (0$38e0$90)
Alcohol consumption and cognitive
function in late life: a longitudinal
community study [113].
Cohort study on 1098 non-
demented elderlies
Reduction cognitive
test or neurocognitive
tests
Minimal and moderate drinker
vs. nondrinker
For any increase of one SD in the
reduction of MMSE the risk of being
minimal drinker vs. that of an
abstainer was 0.3 (0.14e0.65) and
0.08 (0.02e0.28) that of moderate
drinkers
Alcohol intake and risk of
dementia [112]
Cohort study on 980 non-
demented elderlies
Dementia (260) AD (199) Three vs. zero servings of
wine
0.55 (0.84e0.39)
Current alcohol consumption and
its relationship to incident
dementia [115]
Cohort study on 3202 non-
demented elderlies (75 years)
Dementia (217) AD (111) Any kind of alcohol intake vs.
no intake
0.71 (0.53e0.96) dementia
0.58 (0.38e0.89) AD
Alcohol consumption, mild cognitive
impairment, and progression to
dementia [114]
Cohort study on 121 MCI
subjects
Dementia (14) <1 drink/d vs. no intake 0.15 (0.03e0.78)
Alcohol, dementia and cognitive
decline in the elderly: a systematic
review [116]
Meta-analysis of 26 cohort and
caseecontrol studies
Dementia and cognitive
decline
Small amounts of alcohol
intake
0.63 (0.53e0.75) dementia
0.57 (0.44e0.74) AD
Alcohol consumption as a risk factor
for dementia and cognitive decline:
meta-analysis of prospective
studies [117]
Meta-analysis of 15 cohort
studies
Dementia, VAD, AD Light to moderate intake vs.
no intake
0.74 (0.61e0.91) dementia
0.75 (0.57e0.98) VAD
0.72 (0.61e0.86) AD
AD, Alzheimer’s disease; VAD, Vascular dementia; MCI, Mild cognitive impairment; MMSE, Mini Mental Status Examination; CI, Confidence Interval.
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Moderate alcohol use and health 497be analysed here because of known problems in the inter-
pretation of results from epidemiological, mainly case-
econtrol, studies. In fact, most alcohol-related liver cancers
follow cirrhosis, which leads to a reduction of alcohol
drinking and, thus, to a substantial underestimation of the
real associations [131]. Therefore, quantification of risks for
low-to-moderate alcohol consumption and liver cancer re-
mains unresolved. Alcohol drinking might be inversely asso-
ciated to kidney cancer and non-Hodgkin lymphoma [128].
These issues, however, will not be discussed here.
Establishing if there is or not any positive association be-
tween low doses of alcohol and some cancers known to be
alcohol-related is particularly important [132], as it is still
unclear whether there is an alcohol threshold below which
alcohol drinking would not affect cancer development.
Figure 1 shows the main results for light alcohol drinking,
defined as one or few drinks/d, from meta-analyses of
studies on selected digestive tract and larynx cancers
[133e137]. Summary data on light drinking and breast
cancer risk were extracted from the collaborative re-
analysis of 53 epidemiological studies of breast cancer
[138] and from the Million Women Study [139].
For oral and pharyngeal cancer, two meta-analyses,
based on 19 caseecontrol studies and one cohort study,
provided evidence that an increased risk is present also at
low doses of alcohol consumption [136,140] (overall RR
1.21 (95% CI, 1.10e1.33) for one or few drinks/d vs. Non-/
occasional drinkers) [136]. The corresponding estimates
were 1.17 (95% CI, 1.01e1.35, based on nine studies) for
oral cavity and 1.23 (95% CI, 0.87e1.73, based on five
studies) for pharyngeal cancers [140]. The sensitivity an-
alyses provided no evidence for a substantial influence of
studies reporting estimates unadjusted for smoking.
A meta-analysis of oesophageal squamous cell carcinoma
reported an association with low doses of alcohol similar to
that of oral and pharyngeal cancer [134]. The summary RRs
for light drinkingwere 1.31 (95%CI, 1.10e1.57) for theoverall
analysis, based on 26 studies and 1.35 (95% CI, 0.92e1.98) for
cohort studies alone (8 studies). When the analysis was
stratified by geographical area, the association was stronger
in Asia (RRZ 1.63; 95%CI, 1.20e2.22) than in other regions ofFigure 1 Moderate alcohol use and cancer risk in selected
sites. RR, relative risk for alcohol intakes of 1 drink/d, as
compared with abstainers and occasional drinkers.the world (RR Z 1.17; 95% CI, 0.99e1.39), suggesting a po-
tential effect modification by environmental or genetic sus-
ceptibility. No increase in risk by consumption of low doses of
alcohol was observed in never-smokers (RRZ 0.74; 95% CI,
0.47e1.16), but the estimate was based on five studies only.
By contrast, laryngeal cancer was not associated with
alcohol consumption up to one drink/d [135]. The summary
RR for light drinking, based on 10 caseecontrol and two
prospective studies, was 0.88 (95% CI, 0.71e1.08). Results
were unaffected by several subgroup analyses, including
that adjusted for smoking.
Almost 50 studies provided information on low doses of
alcohol and colorectal cancer risk [133]. No overall associ-
ation was reported with either colorectal (RR Z 1.00; 95%
CI, 0.95e1.05), or colon (RR Z 0.96; 95% CI, 0.90e1.02) or
rectal (RRZ 1.06; 95% CI, 0.98e1.14) cancers. Results were
consistent across strata of sex, geographical area and
various other covariates.
A meta-analysis on alcohol and pancreatic cancer found
strong evidence supporting the lack of positive associations at
low-to-moderate alcohol intakes defined as less than three
drinks/d [137]. Seventeen caseecontrol and seven cohort
studies were included and the summary RR was 0.92 (95% CI,
0.86e0.97). The estimates were almost the same when case-
econtrol or prospective studies were considered separately.
When the analyses were repeated comparing consumption of
one or less drink/d to non-occasional drinkers, the odds ratio
(OR) was 0.91 (95% CI, 0.86e0.98). Similarly, in the PanScan
study [141], the pooled OR was, if anything, higher in non-
drinkers (OR Z 1.19; 95% CI, 0.97e1.48) as compared with
drinkers of less than 5 g de1 of alcohol; also, therewas no clear
association up to consumption of <30 g de1.
In a collaborative meta-analysis on breast cancer [138],
the RRs were 1.01 (p > 0.05) for women reporting alcohol
consumption<5 g/d and 1.03 (p> 0.05) for those consuming
5e14 g/d, as compared with women who did not drink. The
MillionWomen Study [139] foundRRs of 1.00 (p> 0.05) for2
drinks/week, that is,<3 g/d of alcohol and 1.08 (p< 0.05) for
3e6 drinks/week, that is, around 4e8 g/d, compared with
non-drinkers. Exclusive consumption of wine showed a
similar risk pattern. Thus, results for breast cancer are not
totally consistent, but indicate a small increase in risk even for
lightdrinking, in theorderofonedrink/d.Thisfindingmayhave
different impact on women according to their menopausal
state: indeed, in young women, especially those with familiar
history of cancer, even a small increase of breast cancer risk by
moderate alcohol consumption would be unacceptable
because it would not be counterbalanced by a concomitant
positive effect on a very low cardiovascular risk. In contrast, a
small increase of breast cancer risk by moderate alcohol use in
post-menopausal womenwould appear negligible with respect
to the substantial reduction of a high cardiovascular risk.
In summary, moderate drinking of up to one drink/d leads
to an increased risk of 20e30% of oral and pharyngeal cancer
and of oesophageal squamous cell carcinoma, though these
estimates remain open to discussion due to under-reporting.
No significant association emerges with the risk of laryngeal,
colorectal and pancreatic cancers. An increased risk of
breast cancer appears at intakes of three to six drinks/week.
A positive association between alcohol and liver cancer has
been established, but no reliable quantification of the risks
for low-to-moderate alcohol consumption is as yet possible.
498 A. Poli et al.In terms of attributable fraction of cancers that would be
eliminatedby restricting alcohol consumption, about 390,000
(3.6%) cancers and 230,000 (3.5%) cancer deaths were
attributed in 2002 to worldwide alcohol drinking [142]. These
included over 5% of cancers and cancer deaths in men and
about 1.5% of cancers and cancer deaths in women. Restric-
tion of alcohol drinking to the limits indicated by the Euro-
peanCodeAgainst Cancer [143] (20 g/d formenand 10 g/d for
women) would avoid about 90% of cancers and cancer deaths
in men and over 50% of cancers in women, that is about 330/
360,000 cancer cases and about 200/220,000 cancer deaths
(Bagnardi et al., 2012). Avoidance or limitation of alcohol
consumption to two drinks/d for men and one drink/d for
women is, therefore, a global public-health priority.Alcohol and all-cause mortality
Themost objectiveway toevaluate the role of alcohol in health
is to assess total mortality (i.e., for all causes) associated with
its use. Infarction, risks and benefits are, in this manner,
compared with the same epidemiological hard ‘end’ point.
The association between total mortality and alcohol
consumption not only depends on quantities and drinking
behaviour, but also on the distribution of causes of death in
the population at study. Further to the first study that
showed a ‘J’-shaped association between alcohol use and
all-cause mortality [144], a meta-analysis combined the
results of 34 prospective studies and investigated the as-
sociation between alcohol consumption and all-cause
mortality in over 1 million apparently healthy subjects.
The results indicate that alcohol intake up to 40 g/d was
inversely associated with reduction of all-cause mortality, a
maximum effect being apparent at about 6 g of ethanol per
day. More than 3e4 drinks/d, conversely, were associated
with a progressive linear increase in overall mortality [3].
This meta-analysis also separately analysed men and
women [3]; maximal theoretical protection was similar in
both sexes (mean reductionw18%, at about 6 g/d, i.e., half
a drink/d). The ‘reversion point’, that is the dose of alcohol
associated with the same mortality as that observed in theFigure 2 Relative risk of all-cause mortality and alcohol
consumption in men and women. Data are from Di Castelnuovo
et al. 2006 [3].control group of abstainers, was reached at 1e1.5 drinks/
d in women and at about 3 drinks/d in men (Fig. 2). Clinical
and biochemical data suggest that, indeed, women are
more prone to the noxious effects of alcohol than men.
Another meta-analysis of seven prospective studies of
12,553 cardiovascular (acute myocardial infarction, stroke,
or coronary disease) patients confirmed the risk reduction
associated with moderate alcohol use, with a maximal
significant decrease by 18% associated with 5e10 g/d of
ethanol, which is maintained up to 26 g/d [12]. Even though
we do not currently have enough data on secondary pre-
vention in women, it is conceivable that their ‘allowed’
dose be similar to that of healthy women [145,146]. On the
contrary, alcoholic patients with previous myocardial
infarction exhibit a risk level for all-cause mortality that is
double than that of regular and moderate drinkers [16].
Patients with CVD who drink >3 drinks/d should be warned
of the risk of haemorrhage associated with alcohol abuse
concomitant with acetylsalicylic-based drugs [145]
Also in the elderly, moderate alcohol use is associated
with reduced all-cause death. In a study of 2000 subjects
between 55 and 65 years of age at enrolment and followed
up for an average of 20 years, total mortality was halved e
after 15 years e in moderate drinkers as compared with
teetotallers [147].
Starting from the second half of the 1990s, several
epidemiological studies have documented the existence of
a ‘J’-shaped curve that describes the association of alcohol
use (and abuse) and total mortality. This curve also in-
dicates a ‘window’ of consumption that might be incorpo-
rated into healthy lifestyles. Likewise, heavy drinking
should be firmly discouraged.Differential health effects of the various
alcoholic beverages
Alcoholic beverages contain both ethanol and other com-
ponents. The quality and quantity of the latter differs
greatly between wine, beer and spirits, as well as within
these categories (red vs. white wine, different beers, etc.).
While the role of ethanol in human health has been eluci-
dated to a great extent, that of the non-alcoholic compo-
nents is less clear. Several experimental studies (in vitro
and in animals) suggest that these components (in partic-
ular, polyphenols) might play important protective roles in
human health [148,149]. Therefore, it has been hypoth-
esised that polyphenol-rich alcoholic beverages such as red
wine might be superior, in terms of healthy effects, to
polyphenol-poor beverages. Particular attention has been
paid to resveratrol, to which several of the alleged healthy
effects of wine have been attributed, even though no
human data are available [150]. Indeed, red wine contains
not only resveratrol but phenols, tannins and flavonoids
such as catechins and quercetin [151]. Some experimental
evidence suggests that these components are endowed
with healthful characteristics [152], such as antioxidant,
anti-thrombotic and anti-inflammatory properties. As pla-
que formation is partially due to the oxidation of LDL within
the arterial wall, polyphenols might retard this process and
reduce atheroma formation [153]. Polyphenols such as
resveratrol and quercetin inhibit platelet function and
Moderate alcohol use and health 499tissue factor, in turn reducing plaque formation. These
effects are independent of the intake of anti-platelet drugs
such as aspirin [154]. In vitro, resveratrol interferes with
the formation of inflammatory mediators by leucocytes,
reduces thrombogenicity linked to adhesion molecules and
prevents thrombosis in animals via nitric oxide formation
[155]. Wine consumption too has been associated with
decreased concentrations of inflammatory markers such as
CRP and higher levels of long-chain omega-3 fatty acids
[156]. Notably, red wine is the alcoholic beverage richest in
polyphenols (though it contains resveratrol only in small
amounts), but beer and some spirits also contain marked
quantities of these compounds [150]. Indeed, polyphenols
from wine and beer have been suggested to positively
affect CVD, diabetes, some cancers, cognitive decline,
Alzheimer’s disease and respiratory tract disorders
[150,157].
Even though data from basic research consistently suggest
favourable biological effects of polyphenols, epidemiological
evidence in support of these effects in humans is scant
[4,150,157,158]. As an example, the potential differences
between wine and beer, as far as cardiovascular pathology
and total mortality are concerned, have been recently
compared by a meta-analysis that involved over 280,000
subjects [159]. The conclusion indicates that the effects of
wine and beer do not differ significantly, reiterating the hy-
pothesis that ethanol plays a major cardioprotective role
[159] regardless of the polyphenolic content of the various
beverages. No comparative data on wine vs. beer and spirits
are available on total mortality, nor do we have enough evi-
dence to say that red wine exerts effects different from that
of white wine [24,159]. Concerning other pathological con-
ditions, epidemiological data comparing wine and beer are
scant and inconclusive [4,150,157,158]. Some authors
believe that the type of alcoholic beverage determining the
strongest event reduction in a particular country is the one
most consumed locally [160].
In conclusion, the hypothesis that the antioxidant and anti-
inflammatory properties of non-alcoholic components might
determine health effects different from that of ethanol is
intriguing, but e at present e only suggested by laboratory
data but not by conclusive epidemiological evidence.
Conclusions
Dozens of epidemiological studies and the meta-analyses that
analysed their results clearly show a statistically significant
association between moderate alcohol consumption, that is
two or three drinks/d or 24e36 g of ethanol/d formen and one
to two drinks/d or 12e24 g of ethanol/d for women and risk
reductionof specific clinical events, namely those involving the
cardio-circulatory system such as atherosclerosis, myocardial
infarction or ischaemic (though not haemorrhagic) stroke. This
association e which concerns both primary and secondary
preventione appears tobe largely independentof confounding
factors, as the inclusion of ‘sick quitters’ in the control groups
of abstainers or the socioeconomic status of the cohorts. In
population studies, the incidence of other common patholog-
ical conditions such as T2DM, dementia and osteoporosis also
appears to be positively influenced by moderate alcohol use.
Moderate alcohol use appears on the other hand to be
associated with modest but significant increased risk ofcancers of the upper respiratory and gastrointestinal tracts,
as well as of breast cancer.
The association between ethanol intake and all-cause
mortality e which computes the overall effects on different
diseases e follows the well-known ‘J’-shaped curve: mortal-
ity amongmoderate drinkers is significantly lower than that of
teetotallers and that of heavy drinkers. Thenadir of this curve
is located at consumption levels of approximately one drink/
d; the mortality rate reverts to the levels of abstainers at
consumptionof 40g/d inmenand20e25g/d inwomen.Above
these levels, overall mortality exceeds that of teetotallers.
The available data, namely the time sequence between
exposure and effects, the doseeresponse association and the
biological plausibility of theeffects, suggest that theobserved
effects of alcohol are likely to be causal. In particular, mod-
erate alcohol use favourably influences known risk factors for
CVD such as plasma levels of HDL-c, fibrinogen, CRP, etc.
These systemic effects might indeed explain the association
between intake levels and cardiovascular risk reduction.
Available data strongly suggest that it is ethanol rather that
someothernon-alcoholiccomponent thatexerts theproposed
protective effects, even though an additive effect of, for
example, polyphenols cannot be ruled out and is plausible.
Moreover, the protective effects of alcohol only appear if its
consumption is moderate and regular over time. Binge drink-
ing, for example on limited occasions such as theweekends, is
not associated with any positive effect and should be strongly
discouraged. This caveat also applies to those who need to
drive automobiles or use dangerous equipment.
The bulk of available data allows proposing some sug-
gestions and guidelines, addressed to physicians and health
professionals:
1) In adults and in the elderly (regardless of sex), sponta-
neous consumption of alcoholic beverages within 30 g
ethanol/d, that is wtwo drinks/d for men and 15 g/d,
that is wone drink/d for women are to be considered
acceptable and do not deserve intervention by the pri-
mary care physician or the health professional in charge.
In fact, there is no evidence to suggest complete
abstention from alcohol drinking by moderate users.
2) Patientswith increasedrisk for specificdiseases, forexample
women with familiar history of breast cancer, or subjects
with familiar history of early CVD or cardiovascular patients
should discuss their drinking habits with their physician.
3) Noabstainer shouldbeadvised todrink for health reasons.
4) Alcohol use must be discouraged in specific physiological
or personal situations or in selected age classes (children
and adolescents, pregnant and lactating women and
recovering alcoholics). Moreover, the possible in-
teractions betweenalcohol and acuteor chronic drug use
must be discussed with the primary care physician.
Disclosure to the lay public of the available notions be-
tween moderate alcohol use and health is debated and calls
for caution. We propose that experts accurately communi-
cate the health benefits and risks of alcohol consumption to
the media and to the public, based on our current under-
standing and available evidence. In particular, the ‘J’-curve,
demonstrating potential health benefits of low-to-moderate
alcohol consumption and increased risk for degenerative
disease (mainly beginning at the fourth decade of life)
500 A. Poli et al.associated with abstinence or excessive consumption,
including the concentrated use of alcohol over short periods
(binge drinking), needs to be judiciously and carefully
explained.
The choice to consumealcohol should bebased on individual
considerations, taking into account the influence on health and
diet, the risk of alcoholism and abuse, the effect on behaviour
and other factors that may vary with age and lifestyle.
Moderation in drinking and development of an associ-
ated lifestyle culture should be fostered.Appendix 1. Scientific societies that have
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